Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 2Spinal Cord Neoplasms 1Sarcoma, Kaposi 1Optic Nerve Glioma 1Oligodendroglioma 1Neurofibromatosis 2 1Neurofibromatoses 1Neoplasms by Histologic Type 1Meningioma 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1HIV Infections 1Familial ependymoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1AIDS-related Kaposi sarcoma 1

Interventions

mirdametinib 3Imatinib Mesylate 3Surveys and Questionnaires 2tipifarnib 1talimogene laherparepvec 1pirfenidone 1nilotinib 1emvododstat 1diphenylcyclopropenone 1cabozantinib 1binimetinib 1Sunitinib 1Sirolimus 1Sevoflurane 1Propofol 1Percutaneous Collagen Induction 1Nitrous Oxide 1Magnetic Resonance Spectroscopy 1Lidocaine 1Lasers, Solid-State 1Lasers 1Glycopyrrolate 1Dexmedetomidine 1Blood Specimen Collection 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatoses × emvododstat × Clear all
NCT00911248 2019-04-12

PTC299 for Treatment of Neurofibromatosis Type 2

PTC Therapeutics

Phase 2 Terminated
11 enrolled
CNS

Neurofibromatosis 2, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡